Tirzepatide (Zepbound, Mounjaro) is a dual-agonist GLP-1 medication. It works like a GLP-1 agonist, but also targets a hormone called glucose-dependent insulinotropic polypeptide (GIP) to “help break down sugar and fat,” according to Chatham.

Nearly seven in 10 Americans who have taken a GLP-1 medication say the drug’s cost influenced their decision to start or continue treatment, according to a new nationwide Navitus Health Solutions Pulse Survey released today.

In an emotional video, actress and comedian Mo'Nique urged her fans to consider the dangers of using a GLP-1 for weight loss.

ShopRite pharmacies will be giving out free starter packs to customers prescribed weight loss drugs, also known as GLP-1’s. Here's what they include.

The kits, which are available for a limited time, include a guide from the grocer’s dietitians, product samples and coupons.

Chronic cough has not traditionally been listed as a common adverse effect of GLP-1s. According to Jeff Stanley, MD, president of the Virta Medical Professional Corporation of Denver-based Virta Health,

GLP-1 receptor agonists improve glycemic control and weight while reducing cardiovascular events, with tolerability limited by gastrointestinal adverse effects requiring gradual dose escalation. Anti-inflammatory effects,

Ozempic maker's lawsuit, FDA enforcement could curtail sales of less expensive, compounded, versions of popular weight loss drugs.

Drugs like Zepbound and Wegovy are intended for people who are overweight. Some patients are using them after bariatric surgery to keep pounds from creeping back. Others may just want to lose a few pounds.

Reports of people developing scurvy while taking GLP-1 medications are on the rise. Here’s why and how you can reduce your risk.

More recently, Pfizer splashed out $150 million upfront—and put up hundreds of millions more in potential milestones—to acquire worldwide rights to a GLP-1 agonist dubbed YP05002 from Yao Pharma, a subsidiary of Shanghai-based Fosun Pharmaceuticals.